Intellia Therapeutics Inc (NTLA) concluded trading on Thursday at a closing price of $32.12, with 4.11 million shares of worth about $132.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.89% during that period and on Thursday the price saw a loss of about -2.07%. Currently the company’s common shares owned by public are about 96.11M shares, out of which, 94.06M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 24 times over the past 12 months. They bought 313,877 shares in 18 of the transactions. In 6 selling transactions, insiders dumped 8,845 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 18.18% in past 5 days and over the past one month there was a price change of 30.62%. Year-to-date (YTD), NTLA shares are showing a performance of 5.35% which decreased to -20.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $22.67 but also hit the highest price of $47.48 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 1.61 million. The stock is currently trading 17.46% above its 20-day simple moving average (SMA20), while that difference is up 14.64% for SMA50 and it goes to -5.30% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 96.11M outstanding shares and institutions hold larger chunk of about 85.49% of that.
The stock has a current market capitalization of $3.09B and its 3Y-monthly beta is at 1.79. It has posted earnings per share of -$5.42 in the same period. It has Quick Ratio of 8.67 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 8.96% while standing at 6.89% over the month.
Analysts are in expectations that Intellia Therapeutics Inc (NTLA) stock would likely to be making an EPS of -$1.38 in the current quarter, while forecast for next quarter EPS is -$1.29 and it is -$5.62 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.58 which is -$1.02 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.17 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -2.55% while it is estimated to decrease by -1.39% in next year. EPS is likely to grow at an annualized rate of 30.00% for next 5-years, compared to annual growth of -22.30% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 23, 2024 offering a Neutral rating for the stock and assigned a target price range of between $136 and $32 to it. On April 13, 2023, Canaccord Genuity Initiated their recommendations, while on March 21, 2023, Bernstein Initiated their ratings for the stock with a price target of $54. Stock get an Outperform rating from BMO Capital Markets on March 14, 2023.
